Table 2.
Treatment for patients with COVID-19 related ARDS
| COVID-19 treatment, n (%) | Total number of patients (n = 57) |
|---|---|
| Azithromycin | 48 (84.2) |
| Hydroxychloroquine | 50 (87.7) |
| Remdesivir | 3 (5.3) |
| Tocilizumab | 15 (26.3) |
| Sarilumab | 2 (3.5) |
| Anakinra | 1 (1.8) |
| Corticosteroids | 44 (77.2) |
| Convalescent plasma | 7 (12.3) |
| Mesenchymal stem cell therapy | 3 (5.3) |
| Anticoagulation therapies, n (%) | |
| Therapeutic anticoagulation | 42 (73.4) |
| LMWH | 25 (43.9) |
| UFH | 16 (28.1) |
| DOAC | 1 (1.8) |
| Preventive anticoagulation | 13 (22.8) |
| LMWH | 6 (10.5) |
| UFH | 7 (12.3) |
| No anticoagulation | 2 (3.5) |
| ARDS treatment, n (%) | |
| Prone positioning | 33 (57.9) |
| Neuromuscular blockade | 44 (77.2) |
| Pulmonary vasodilator | 20 (35.1) |
| Organ support, n (%) | |
| Invasive Ventilation | 57 (100) |
| Tracheostomy | 12 (21.1) |
| Hemodialysis | 15 (26.3) |
| ECMO | 4 (7.0) |
LMWH low molecular weight heparin; UFH unfractionated heparin; DOAC direct oral anticoagulant; ARDS acute respiratory distress syndrome; ECMO extracorporeal membrane oxygenation